General information about company
Scrip code*		544184
NSE Symbol*		BOROSCI
MSEI Symbol*		NOTLISTED
ISIN*		INE02L001032
Name of company		BOROSIL SCIENTIFIC LIMITED
Type of company		Main Board
Class of security		Equity
Date of start of financial year		01-04-2025
Date of end of financial year		31-03-2026
Date of board meeting when results were approved		11-08-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange		11-08-2025
Description of presentation currency		INR
Level of rounding		Lakhs
Reporting Type		Quarterly
Reporting Quarter		First quarter
Nature of report standalone or consolidated		Consolidated
Whether results are audited or unaudited for the quarter ended		Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting		Multi segment
Description of single segment
Start date and time of board meeting		11-08-2025 12:00
End date and time of board meeting		11-08-2025 13:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion

Financial Results – Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2025	01-04-2025
Date of end of reporting period		30-06-2025	30-06-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	9597.64	9597.64
	Other income	291.8	291.8
	Total income	9889.44	9889.44
2	Expenses
(a)	Cost of materials consumed	3355.26	3355.26
(b)	Purchases of stock-in-trade	210.03	210.03
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-109.49	-109.49
(d)	Employee benefit expense	2005.75	2005.75
(e)	Finance costs	38.37	38.37
(f)	Depreciation, depletion and amortisation expense	487.62	487.62
(g)	Other Expenses
1	Other Expenses	3648.79	3648.79
	Total other expenses	3648.79	3648.79
	Total expenses	9636.33	9636.33
3	Total profit before exceptional items and tax	253.11	253.11
4	Exceptional items	-661.31	-661.31
5	Total profit before tax	-408.2	-408.2
6	Tax expense
7	Current tax	0	0
8	Deferred tax	12.76	12.76
9	Total tax expenses	12.76	12.76
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	-420.96	-420.96
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	-420.96	-420.96
17	Other comprehensive income net of taxes	-1.5	-1.5
18	Total Comprehensive Income for the period	-422.46	-422.46
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent	-416.43	-416.43
	Total profit or loss, attributable to non-controlling interests	-4.53	-4.53
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent	-417.9	-417.9
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	-4.56	-4.56
21	Details of equity share capital
	Paid-up equity share capital	889.46	889.46
	Face value of equity share capital	1	1
22	Reserves excluding revaluation reserve
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	-0.47	-0.47
	Diluted earnings (loss) per share from continuing operations	-0.47	-0.47
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
iii	Earnings per equity share (for continuing and discontinued operations)
	Basic earnings (loss) per share from continuing and discontinued operations	-0.47	-0.47
	Diluted earnings (loss) per share from continuing and discontinued operations	-0.47	-0.47
24	Debt equity ratio	0	0	Textual Information( 1)
25	Debt service coverage ratio	0	0	Textual Information( 2)
26	Interest service coverage ratio	0	0	Textual Information( 3)
27	Disclosure of notes on financial results	Textual Information(4)

Text Block

Textual Information(4)

Notes on Unaudited Consolidated Financial Results for the quarter ended 30th June, 2025:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 11th August, 2025. The Statutory Auditors of the Company have carried out a Limited Review of the above results.

2. Pursuant to exercise of the options issued under “Borosil Scientific Limited - Special Purpose Employee Stock Option Plan 2023”, the Company has made allotment of 12,625 Equity Shares of the face value of Re. 1/- each for the quarter ended 30th June, 2025, which has resulted into increase of paid up Equity Share Capital by Rs. 0.13 lakhs and Securities Premium by Rs. 13.80 lakhs

3. As informed earlier, the Company had introduced a Voluntary Retirement Scheme (VRS) for the eligible workers at its plant situated at Village Ambad, Nashik, Maharashtra . During the quarter, the Company entered into a Memorandum of Settlement, with the Bhartiya Kamgar Sena (BKS), outlining the terms of final settlement under VRS. BKS is a trade union registered under Trade Union’s Act, 1926, representing the said eligible workers. The above settlement resulted total expenditure of Rs. 661.31 lakhs (including professional fees related to the above) and shown as an exceptional item in the above results.

4. The figures for the corresponding previous period/year have been rearranged/ regrouped, wherever necessary, to make them comparable. The figures for the quarter ended 31st March, 2025 is the balancing figures between the audited figures of the full financial year and the published year to date figures upto the third quarter of the respective financial year.

For Borosil Scientific Limited
(Formerly Known as Klass Pack Limited)

Place: Mumbai Vinayak Patankar
Date :11st August, 2025 Whole-time Director & CEO
(DIN 07534225)

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2025	01-04-2025
Date of end of reporting period		30-06-2025	30-06-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Consolidated	Consolidated
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
1	Scientific – Laboratory Glass & equipment and Process System	6311.97	6311.97
2	Glassware	3223.65	3223.65
3	Others	62.02	62.02
	Total Segment Revenue	9597.64	9597.64
	Less: Inter segment revenue	0	0
	Revenue from operations	9597.64	9597.64
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
1	Scientific – Laboratory Glass & equipment and Process System	838.89	838.89
2	Glassware	-227	-227
3	Others	23.92	23.92
	Total Profit before tax	635.81	635.81
	i. Finance cost	38.37	38.37
	ii. Other Unallocable Expenditure net off Unallocable income	1005.64	1005.64
	Profit before tax	-408.2	-408.2
3	(Segment Asset - Segment Liabilities)
	Segment Asset
1	Scientific – Laboratory Glass & equipment and Process System	18713.47	18713.47
2	Glassware	10805.16	10805.16
3	Others	194.23	194.23
	Total Segment Asset	29712.86	29712.86
	Un-allocable Assets	20028.78	20028.78
	Net Segment Asset	49741.64	49741.64
4	Segment Liabilities
	Segment Liabilities
1	Scientific – Laboratory Glass & equipment and Process System	5106.61	5106.61
2	Glassware	2050.66	2050.66
3	Others	17.03	17.03
	Total Segment Liabilities	7174.3	7174.3
	Un-allocable Liabilities	2450.67	2450.67
	Net Segment Liabilities	9624.97	9624.97
	Disclosure of notes on segments	Textual Information(1)

Text Block

Textual Information(1)

Note :

As per Indian Accounting Standard 108 on ‘Operating Segment’ (Ind-AS 108), the Company has reported "Segment information", as described below:

Scientific – Laboratory Glass & equipment and Process System:- Comprising of items used in laboratories, production floor and research and development

Glassware:- Pharmaceutical primary packaging and domestic glassware items

Others :- Comprising of Filter Paper etc.

Unallocated:- Consists of income, expenses, assets and liabilities which can not be directly identified to any of the above segments.

Other Comprehensive Income
Date of start of reporting period		01-04-2025	01-04-2025
Date of end of reporting period		30-06-2025	30-06-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Consolidated	Consolidated
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
1	Re-measurement gains / (losses) on defined benefit plans	-2.00	-2.00
	Total Amount of items that will not be reclassified to profit and loss	-2.00	-2.00
2	Income tax relating to items that will not be reclassified to profit or loss	-0.50	-0.50
3	Amount of items that will be reclassified to profit and loss
	Total Amount of items that will be reclassified to profit and loss
4	Income tax relating to items that will be reclassified to profit or loss	0.00	0.00
5	Total Other comprehensive income	-1.50	-1.50

Details of Impact of Audit Qualification
Whether results are audited or unaudited		Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Consolidated results		Yes
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	M/s. Chaturvedi & Shah LLP	Yes	30-06-2026

General information about company

Financial Results – Ind-AS

Text Block

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results

Text Block

Other Comprehensive Income

Details of Impact of Audit Qualification